Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | SIK1 | P57059 | 1/20 | 0.48 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 17/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 15/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309511 | 1.00 | SIK2 (0.51) | SIK2CSF1RSIK1SIK3FGFR4 | |
| SCHEMBL25882388 | 0.83 | SIK2 (0.49) | SIK2CSF1RSIK1SIK3FGFR4 | |
| SCHEMBL30309504 | 0.83 | SIK2 (0.68) | SIK2CSF1RSIK1SIK3FGFR4 | |
| SCHEMBL23978372 | 0.83 | SIK2 (0.68) | SIK2CSF1RSIK1SIK3FGFR4 | |
| SCHEMBL23978120 | 0.83 | SIK2 (0.51) | SIK2CSF1RSIK1SIK3FGFR4 | |
| SCHEMBL30309533 | 0.83 | SIK2 (0.51) | SIK2CSF1RSIK1SIK3FGFR4 | |
| SCHEMBL30309560 | 0.83 | SIK2 (0.49) | SIK2CSF1RSIK1SIK3FGFR4 | |
| SCHEMBL30309486 | 0.79 | SIK2 (0.46) | SIK2CSF1RSIK1SIK3FGFR4 | |
| SCHEMBL30309495 | 0.79 | SIK2 (0.47) | SIK2CSF1RSIK1SIK3FGFR4 | |
| SCHEMBL25882416 | 0.79 | SIK2 (0.46) | SIK2CSF1RSIK1SIK3FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | SIK2 116/4885CSF1R 28/4885SIK1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.